| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,778 |
4,976 |
$303K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
944 |
632 |
$16K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,091 |
1,584 |
$15K |
| J2010 |
Injection, lincomycin hcl, up to 300 mg |
1,229 |
964 |
$15K |
| 87428 |
|
236 |
226 |
$13K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
835 |
616 |
$10K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,503 |
474 |
$9K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,655 |
1,216 |
$6K |
| 81025 |
|
861 |
626 |
$4K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
631 |
444 |
$3K |
| 81001 |
|
683 |
476 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
12 |
12 |
$607.10 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,198 |
952 |
$365.84 |
| 87807 |
|
126 |
59 |
$286.47 |
| 86580 |
|
14 |
12 |
$83.28 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
82 |
67 |
$50.96 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
48 |
13 |
$0.00 |